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ABSTRACT 
Wavelength comparisons have indicated that circadian phase-shifting and enhancement of 
subjective and EEG-correlates of alertness have a higher sensitivity to short wavelength 
visible light.  The aim of the current study was to test whether polychromatic light enriched 
in the blue portion of the spectrum (17000 K) has increased efficacy for melatonin 
suppression, circadian phase-shifting, and alertness as compared to an equal photon density 
exposure to a standard white polychromatic light (4000 K). Twenty healthy participants 
were studied in a time-free environment for 7 days. The protocol included two baseline 
days followed by a 26-h constant routine (CR1) to assess initial circadian phase. Following 
CR1, participants were exposed to a full-field fluorescent light (1 x 1014 photons/cm2/s, 
4000 K or 17000 K, n=10/condition) for 6.5h during the biological night.  Following an 8 
h recovery sleep, a second 30-h CR was performed.  Melatonin suppression was assessed 
from the difference during the light exposure and the corresponding clock time 24 h earlier 
during CR1. Phase-shifts were calculated from the clock time difference in dim light 
melatonin onset time (DLMO) between CR1 and CR2. Blue-enriched light caused 
significantly greater suppression of melatonin than standard light ((mean ± SD) 
70.9±19.6% and 42.8±29.1%, respectively, p<0.05). There was no significant difference 
in the magnitude of phase delay shifts. Blue-enriched light significantly improved 
subjective alertness (p<0.05) but no differences were found for objective alertness. These 
data contribute to the optimization of the short wavelength-enriched spectra and intensities 
needed for circadian, neuroendocrine and neurobehavioral regulation. 
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1.  Introduction 
   The human circadian pacemaker is exquisitely responsive to ocular light exposure [1].  
Photic information is transduced by the retinohypothalamic tract to the suprachiasmatic 
nucleus (SCN) and then to the pineal gland via a multisynaptic pathway [2].  The SCN-
pineal, but not the retinae-SCN pathways need to be intact for the secretion of melatonin, 
even in the absence of light [3,4]. By way of this neuroanatomy, cycles of light and dark 
which are detected through the eyes entrain SCN neural activity which, in turn, entrains 
the rhythmic synthesis of multiple physiological, endocrinological, metabolic and 
behavioral systems including melatonin secretion from the pineal gland [5]. 
   In virtually all species including humans, high levels of melatonin are secreted during 
the night and low levels are secreted during the day [6].  Ocular light exposure affects 
melatonin secretion in two major ways –light exposure during the biological night causes 
the acute suppression of melatonin [7] and light exposure throughout the 24-hour day shifts 
its rhythm according to a Phase Response Curve [8]. The strong circadian control of 
melatonin and its sensitivity to light timing mean that melatonin is often used as a marker 
of the circadian clock [9]. 
   Light is detected primarily by a specialized subset of intrinsically photosensitive retinal 
ganglion cells (ipRGCs) [10,11,12,13].  These non-rod, non-cone photoreceptors express 
the photopigment melanopsin which has a short wavelength peak sensitivity around 480 
nm [14,15]. 
   Using this defined spectral sensitivity of the melanopsin photopigment in ipRGCs, 
multiple studies have examined the spectral sensitivity of melatonin suppression, circadian 
phase shifting, and the acute effects of alertness using narrowband (15 nm or greater 
halfpeak bandwidth) or monochromatic (less than 15 nm halfpeak bandwidth) light sources.  
Monochromatic blue light has been shown to cause greater circadian phase shifting and 
acute alerting responses over monochromatic green light [16,17,18,19,20].  
     Studies have also documented short-wavelength sensitivity for neuroendocrine effects 
using broad spectrum polychromatic blue-enriched light evoking stronger melatonin 
suppression than those with relatively less short-wavelength light [21,22].  In both of these 
studies, equal photopic lux bright light exposures of either 1,000 lux [22] or 2,500 lux [21] 
at high CCT (6480-6500K) caused greater increases in melatonin suppression and increases 
core body temperature than low CCT (3000-3150 K) broad spectrum polychromatic light. 
Sato and colleagues reported that a 2 hour light exposure in the early morning caused 
significant acceleration in the rise of core body temperature and fall of salivary melatonin 
secretion from the blue-enriched, high CCT condition [21]. Evening light exposures of 5 
hours were employed by Morita and Tokura causing significant suppression of the 
nocturnal rise urinary melatonin and the fall of core body temperature in the high CCT 
group [22]. These carefully done initial studies, however, were limited in that they 
examined only the acute neuroendocrine effects of relatively intense polychromatic light 
sources.  We built on these results to examine both acute and circadian neuroendocrine 
responses as well as neurobehavioral differences using a standard light source at more 
common lower room illuminances 
   In addition to highly controlled laboratory studies, several real-world applications in 
schools and offices using both static and dynamic lighting manipulations involving blue-
enriched light have demonstrated increased subjective measures of alertness and affect as 
well as improvements in standard tests of cognitive processing speed, concentration and 
reading ability in blue-enriched lighting conditions[23,24,25,26,27]. For example, office 
installation of the fluorescent lamps used in this study on two floors with participants being 
exposed in a counter-balanced order resulted in statistically significant improvements in 
self-reported measures of alertness, mood, performance, evening fatigue, irritability, 
concentration and eye discomfort during the month of 17000 K exposure as compared to 
4000 K [23].  Mott et al. (2012) studied third grade students (age 7-8 years) under the 
Normal (500 lux, 3500K) versus Focus (1000 lux, 6500K) light conditions and found that 
the higher CCT lighting was reported to improve oral reading fluency when assessed over 
a full calendar year [25]. 
   Recently, we conducted a within-subjects study that established full-range fluence-
response curves to three types of fluorescent lamps that differed in their relative emission 
of light in the short wavelength end of the visible spectrum between 400 and 500 nm 
demonstrating that increasing corneal irradiances of light evoked progressively increasing 
suppression of nocturnal melatonin. Comparison of these fluence-response curves supports 
the hypothesis that polychromatic fluorescent light is more potent for melatonin regulation 
when enriched in the short wavelength spectrum [28]. Building on these data, we tested the 
hypothesis that blue-enriched polychromatic fluorescent light (17000 K) can be more 
effective than standard white fluorescent light (4000 K) light for eliciting melatonin 
suppression, enhancement of neurobehavioral function and phase shifting in healthy 
human participants. This carefully controlled comparison of a high color temperature 
polychromatic light source was performed under commonly occurring room illuminances 
while balancing for photon density. 
2.  Materials and Methods 
2.1  Participants 
   A total of 11 males and 9 females (mean age ± SD of 22.1 ± 1.8 years, range -19 to 26 
years) were studied in the Light Research Laboratory of Thomas Jefferson University 
between July 2007 and August 2008. The study was approved by the Institutional Review 
Board of Thomas Jefferson University and all participants gave written informed consent 
prior to entering the protocol. All participants underwent psychological, toxicological, 
physical, and ophthalmological exams including color vision testing.  For at least 10 days 
prior to entry into the seven-day protocol participants maintained a self-selected 8-hour 
sleep/wake schedule with calls to a time- and date-stamped voicemail at bedtime and wake.   
Participants also wore an actigraph (BASIC Motionlogger, Ambulatory Monitoring, Inc., 
Ardsley, NY) to verify bed and wake times during this time.  The exclusion criteria 
included no use of recreational, over-the-counter, or prescription medications inclusive of 
caffeine and alcohol in the 10 days prior to admission.  Toxicological screening for drugs 
of abuse, caffeine and alcohol as well as pregnancy testing, basic metabolic panel, thyroid 
function, and a complete blood count was conducted during screening and on the day of 
entry in the facility. Both groups were gender balanced (5M, 5F in 17000 K group and 4M, 
6F in 4000 K group) and the testing of two sleep parameters from actigraphy revealed no 
differences (Total Sleep Time and Awakenings) from actigraphy revealed no differences 
(p=0.23 and p=0.70, respectively). 
 
2.2  Protocol design 
   Figure 1 provides a diagrammatic representation of the 7-day inpatient protocol.  This 
protocol was adapted from the 9-day protocol used at the Brigham and Women’s Hospital 
[16]. Participants lived in a time-free environment (no windows, timepieces, TV, or 
internet access with continual supervision by trained staff) and remained in their assigned 
room for the duration of the study. During the constant-routine, participants remained 
awake in dim light (< 5 lux) in a semi recumbent position while under direct supervision 
with isocaloric meals (basal energy expenditure x 1.3) being served every two hours. 
 
2.3  Study lighting conditions 
   Ambient light in the facility was produced by ceiling-mounted standard cool-white (4100 
K CCT) 40 W fluorescent lamps (F40T12/841ALTO, Philips Lighting, B.V., Eindhoven, 
Netherlands) placed above matte white acrylic 0.080-inch diffuser panels and controlled 
by a full range dimming system (Model #HLT-2000/3 Dimmer Module with HILUME 
Electronic dimming ballast OPSCU Series, DP-1 dimmer panel, VA-3-4A Control Panel, 
Lutron Corp., Coopersburg, PA). The light intensities in the study rooms were < 80 lux 
maximal (at a height of 122 cm in the vertical plane) on study day 1 and during the first 
eight hours of study day 2.  For the rest of the waking hours of the study, participants were 
kept in constant dim light with illuminances < 5 lux in the vertical plane.  Eight-hour sleep 
opportunities scheduled at the average of the 10 days prior to admission occurred in 
complete darkness.  Daily illuminance/irradiance measures were taken using an IL-
1400BL radiometer/photometer (International Light Technologies, Inc., Peabody, MA).  
This meter had either a model SEL033/Y/W detector or to provide photopic illuminance 
response or SEL033/F/W to provide flat irradiance response and each was annually given 
a full scanned calibration.  All calibrations were traceable to the U.S. National Institute of 
Standards and Technology. 
   Experimental polychromatic light exposures occurred on the night of study day 4 when 
participants underwent a 6.5-hour light exposure (LE) that began 9.25 hours before their 
habitual wake time. Light exposure was timed to correspond to approximately 6.75 h before 
core body temperature minimum, a phase where previous studies produced phase delays 
[16,19].  The 4’ x 4’ light exposure system held both sets of 54 W fluorescent lamps in 
each. A diffuser cover on the front of the panel allowed for a uniform field of light exposure 
for the subject. The panel was attached to an analog dimmer switch to adjust intensity. The 
lamps, as well as the lighting panel unit, were constructed and donated by Philips Lighting, 
B.V. (Eindhoven, Netherlands). An additional neutral density filter panel (0.3 ND 50% 
transmission) that covered the entire light panel surface was used to further adjust the 
intensity of 17000 K light source (Rosco Laboratories, Stamford, CT).  Experimental 
illuminance/irradiance measures were taken using the IL-1400BL radiometer/photometer 
previously described which was held in place by a clear, plastic holder attached in an 
ophthalmologic head holder 30 cm from the panel at approximate eye level of the 
participants. Figure 2 shows the spectral power distributions emitted by the 4000 K and 
17000 K experimental lamps. 
 
  Participants were randomly assigned on the day of entry to experimental polychromatic 
light from a 4000 K or a 17000 K fluorescent lamp (N=10 per condition).  The target 
intensity of the 17000 K lamp was chosen from fluence-response curves for short-duration 
(90-minute) melatonin suppression testing [28]. The ED90, or 90% of the saturating dose 
of light for melatonin suppression for the 17000 K lamp, was chosen for this study.  This 
resulted in an equal photon density of 1 x 1014 photons/cm2/s for both exposure conditions. 
The equivalent irradiance/illuminance of light for the 4000 K and 17000 K lamps were 
40.7 μW/cm2 (134.3 lux) and 50.0 μW/cm2 (128.9 lux), respectively.  The average 
irradiances (± SEM) measured every 30 minutes over the 6.5 h exposure were 40.86 ± 0.12 
μW/cm2 for the 4000 K exposure and 49.99 ± 0.07 μW/cm2 for the 17000 K exposure. For 
140 minutes prior to and for the full duration of the light exposure participants remained 
seated. Participants wore blindfolds for approximately 30 minutes prior to light exposure 
while lights stabilized and intensities were verified.  Participants were seated 30 cm in front 
of the light panel with their chin placed in an ophthalmologic head holder and monitored 
continuously. Participants were asked to maintain a fixed gaze toward the panel for 90 
minutes before resting their head and neck out of the headholder for 10 minutes while 
remaining seated. This sequence was repeated throughout the entire 6.5 h exposure. 
 
2.4  Sleepiness and performance assessments 
   During every hour of wakefulness, participants completed the Karolinska Sleepiness 
Scale (KSS) [29], and visual and auditory psychomotor vigilance tasks (PVTs) [30,31] 
using a personal digital assistant (PDA) (Tungsten E2, Palm, Inc, Sunnyvale, CA). This 
modified visual PVT lasted for five minutes, at the end of which the mean reaction time 
for that trial was displayed for the subject. PDA light measures taken at 12 inches from the 
eye were 1.2 lux and at 24 inches were 0.6 lux, The main measures for each trial for each 
subject were mean reaction time in milliseconds and number of lapses greater than 500 
milliseconds (i.e. number of times the subject took 500 milliseconds or longer to react to 
the target appearing) [30,32,33]. The auditory PVT was completed on a PVT-192 by 
Ambulatory Monitoring, Inc. (Ardsley, NY). The auditory PVT trial was 10 minutes in 
length. The main measures for each trial for each subject were mean reaction time in 
milliseconds and number of lapses greater than 400 milliseconds [31]. 
 
2.5 Sample collection 
   Blood samples (3 ml) were collected through an indwelling intravenous catheter located 
in a forearm vein into 3 ml polystyrene tubes which contained 5.4 mg of K2 
ethylenediaminetetraacetic acid (EDTA) (BD Diagnostics, Franklin Lakes, NJ).  Plasma 
was separated by refrigerated centrifugation, aliquoted into cryogenic vials and stored at -
20˚ C.  Plasma melatonin samples were collected every 60 minutes during constant-routine 
periods on Days 3/5 and every 20 minutes during light exposure. Plasma melatonin 
concentrations were assayed by radioimmunoassay using antiserum described by Rollag 
and Niswender [34].   
   Saliva samples (2ml) were collected with the "Salivette" sampling device (Sarstedt, Inc., 
Hayward, CA).  Specimens were centrifuged and aliquoted into cryogenic vials for storage 
at -20˚ C until assay.  Salivary melatonin samples were collected every 60 minutes during 
constant-routine periods on Days 3/5 and during light exposure.  Salivary melatonin 
concentrations were assayed by radioimmunoassay [35]. Salivary analyses were used as a 
backup measure when plasma samples were missed due to IV line failure.  
 
2.6  Melatonin assays 
   The inter-assay coefficient of variation from the 15 plasma assays run for this experiment 
using the assay from Rollag and Niswender [34] was 17.0%. Coefficient of variation 
calculated from a control sample of 100 pg/ml assayed had 12.3% for intra-assay 
coefficient of variation. The minimum detection limit of this assay is 0.5-2.0 pg/ml 
melatonin.  The inter-assay coefficient of variation from the 7 salivary assays run for this 
experiment using the assay from Vaughan [35] was between 8-12%. Coefficient of 
variation calculated from control samples of 1.83 and 18.99 pg/ml assayed had 2.7% and 
6.9% intra-assay coefficient of variation respectively. The minimum detection limit of the 
salivary assay is 0.5-2.0 pg/ml melatonin. 
 
2.7   Statistics 
   Melatonin suppression (mean ± SD) was calculated from the difference in area under the 
curve (AUC) between melatonin profiles during light exposure and the corresponding 
clock times during the previous melatonin cycle on CR1 [16]. Unpaired, two tailed t-tests 
were used to compare differences in melatonin suppression by exposure to 17000 K lamps 
compared to 4000 K lamps. 
   DLMO25 was calculated for each subject defined from 25% of the fitted three-harmonic 
peak-to-trough amplitude of the melatonin rhythm during the first constant routine. The 
magnitude of phase-shift was determined from differences in clock time between DLMO25 
during the first constant routine (CR1) as compared to the second constant routine (CR2) 
[16]. Unpaired, two tailed t-tests were used to compare differences in phase by exposure 
to 17000 K lamps compared to 4000 K lamps. 
   The data from the visual PVT and the auditory PVT-192 devices were analyzed using 
mixed ANOVA analysis comparing light sources and time was completed using SAS 9.0 
(SAS, Cary, NC).  
   To determine sample size a priori, data from a previous study of the phase shifting effects 
of 460 nm and 555 nm monochromatic light were used to perform a power analysis [16]. 
Using these data, a 1-h phase shifting difference was assumed, with a standard deviation 
of 0.62 h,  value of 0.05, and  value of 0.9. With these assumptions, 10 participants per 
group were calculated to be needed to detect the 1 h phase difference [36]. 
3.0  Results 
3.1  Melatonin suppression 
   As shown in Figure 3, all participants exposed to blue-enriched (17000 K) polychromatic 
fluorescent light had at least 29% melatonin suppression over the entire 6.5 h light exposure 
(range 29-91%). Suppression was more variable among participants exposed to the 
standard (4000 K) polychromatic fluorescent light at the same photon density (range 0-
82%), including 2 individuals with virtually no melatonin suppression.  On average, 
exposure to 6.5 h of 17000 K light caused a significantly greater suppression of melatonin 
(mean ±SD, 70.9 ± 19.6%; n=10) compared with 4000 K light (42.8 ± 29.1%; n=10) 
(p<0.05). The time course of the melatonin suppression response also differed between the 
groups. In the 17000 K condition, the light suppressed melatonin for the entire exposure 
duration and did not return to DLMO levels. In the 4000 K condition, four participants 
failed to suppress plasma melatonin to their DLMO25% level at all and in four other 
participants, melatonin levels recovered to their DLMO25% after ~1-3 hours within the 
light exposure. (1.35 h, 1.67 h, 2.50 h, 3.00 h) (Figure 4) 
 
3.2  Phase shifting 
   Both light exposure conditions caused a phase delay of the onset of the melatonin rhythm 
in all but of the one of the participants. Exposure to 6.5 h of 17000 K light caused a phase 
delay shift with amean ± SDof 2.1 ± 0.6 h; n=10whileexposure to 4000 K light caused a 
phase delay shift of 1.7 ± 1.3 h; n=10. The mean differencedid not reach significance 
(p=0.22) (Figure 3).  Representative 24 h melatonin profiles from an individual in each of 
the light conditions are shown in Figure 5. 
 
3.3 Sleepiness assessment 
   As shown in Figure 6, self-rated sleepiness was lower during the 17000 K light exposure 
as compared to the 4000 K group (p<0.05).  Pre light exposure differences in KSS were 
not significant (p=0.20). Participants in the 4000 K light group consistently reporting being 
sleepier at all time points (p<0.05) during LE compared to the 17000 K light group and 
remained so for 3 hours post light exposure (p<0.05). 
 
3.4 Performance assessment 
   With the visual PVT testing, there was no significant difference between the two light 
groups in the mean visual reaction time (RT) or lapses of attention during, or for the three 
hours after, the light exposure ended.  
   Three participants were eliminated from the auditory PVT analysis for the 4000 K light 
group as their data files were corrupted due to equipment malfunction. For auditory RT, 
there were no significant differences in any parameter during the light exposure but there 
were significant differences between light conditions for RT and lapses > 400 msec for the 
3 hours post LE (p<0.05), with the 17000 K light group having a quicker reaction time and 
fewer lapses than the 4000 K light group. This can be seen in Figure 6.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Fig. 1. Overview of 7-day phase shifting protocol for a subject with a midnight to eight AM 
sleep:wake schedule. The schedule consisted of a 2-day baseline (8-hour:16-hour sleep-wake cycle 
based on each subject’s self-selected sleep-wake times), an initial 26 hour constant routine, a 16 
hour dim light-exposure day with a 6.5 hour experimental light exposure, and a second 30 hour 
constant routine, each preceded and followed by an 8-hour sleep opportunity. [16,19]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4000 K CCT Fluorescent 
17000 K CCT Fluorescent 
  
Fig. 2.  Spectral power distribution for 4000 K (upper panel) and 17000 K (middle panel) light 
sources. Profiles are relatively similar, with the primary difference between 400 and 500 nm. 
Compared to the 4000 K light source, the 17000 K light source emitted substantially more power 
in the blue light part of the spectrum. The lower panel shows calculated irradiances, photopic 
illuminances v(), and human photopigment illuminances relative to the two polychromatic light 
sources used [75]. 
 
 
 
 
 
 
 
 
 
 
 
 
Radiometric and Photometric Values           
(380 -780 nm inclusive) 
Retinal Photopigment Weighted Illuminances 
(α-opic lux) 
 
Photon Flux 
(photons/cm²/s) 
Irradiance 
(µW/cm2) 
Photopic 
Illuminance 
(lux) 
S 
Cone 
Melanopsin 
ipRGC Rod 
M 
Cone 
L 
Cone 
4000K 
Light 1.01E+14 36.3 123 83 79 91 109 120 
17000K 
Light 1.00E+14 39.0 96 190 133 122 107 96 
A.  A. B. 
 
 
 Fig. 3. Melatonin suppression (±SD) as calculated by AUC with plasma (filled circles) or 
salivary (empty circles) levels following exposure to 6.5 h of white 4000 K fluorescent 
light or blue-enriched 17000 K fluorescent light (A).  A greater suppression of plasma 
melatonin occurred under 17000 K fluorescent light compared to 4000 K fluorescent light 
(p<0.05). Phase delay shift (±SD) of the plasma (filled circles) or salivary (empty circles) 
melatonin rhythm as assessed by DLMO following exposure to 6.5 h of white 4000 K 
fluorescent light and blue-enriched 17000 K fluorescent light (B). The phase delay shift, 
was not statistically significant (p=0.22).  
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Fig. 4. Individual melatonin profiles 2 h prior to, during (boxed area) and 4 h after 6.5 h 
exposure to 17000 K (top panel) and 4000 K (bottom panels) light, normalized to each 
individuals’ fitted peak value during the first melatonin cycle on CR1. 
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Fig. 5. The 24 h melatonin profiles on CR1 (filled circles) and CR2 (open circles) from one 
representative individual in each of the LE groups (A & B). Below each (C & D) are the 
calculated melatonin suppression (AUC) during LE (open circles) and the corresponding 
time from CR1 (filled circles) for each of the same individuals.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
p <0.05 
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B. 
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Fig. 6. KSS scores before, during and after LE (filled circles 4000 K; open circles 17000 K, top 
panel). KSS scores were lower, indicating higher alertness, during LE for the 17000 K group versus 
the 4000 K group (p<0.05). Average auditory PVT lapses per hour before, during, and after LE. 
The period of LE is indicated by box (bottom panel) 
 
4.  Discussion 
   Our results demonstrate that both standard (4000 K) and blue-enriched (17000 K) 
fluorescent light at equal photon densities of 1 x 1014 photons/cm2/s suppress plasma 
melatonin in healthy young participants with blue-enriched light eliciting a stronger 
hormonal suppression.  In contrast, phase shifting was not significantly different at this 
intensity between the two light conditions. Subjective measures of alertness using KSS 
support the hypothesis that blue-enriched light exposure significantly improves alertness. 
Objective measures of alertness using PVT, however, did not show any significant 
differences in alertness during the light exposures. In the three hours post-light exposure 
the blue-enriched light group had quicker reaction times and fewer lapses compared to the 
standard light group. 
   This study was based on two dose-response curves for melatonin suppression which 
predicted the photon density at which standard and blue-enriched light would differ the 
most.  The ED90 for the 17000 K dose-response curve with its matching 4000 K dose 
(approximately ED50) was used [28].  Use of these two dose-response curves successfully 
predicted the resultant melatonin suppression observed here.. The blue-enriched 
fluorescent light provided a significantly more consistent phase-delay than standard 
fluorescent light when comparing variances, however, indicating a greater effect on the 
circadian system. Our pre-study power calculations based on monochromatic exposure 
data showed sufficient power to detect an effect on phase shifting but our post-hoc power 
calculation revealed that these data yield a  value of 0.797, at  value of 0.05. This is a 
statistical power level (1-) of 20.3%. In order to obtain a statistical power of 50%, i.e. 
=0.5, each group would need to have 41 subjects, for a total of 82 subjects in the study, 
based upon the mean difference found between the 17000 K and 4000 K groups.  The costs 
of running such a study would be prohibitive and is an obvious limitation to this study. 
 Similarly, the blue-enriched condition also had a more sustained response on melatonin 
suppression. When examining the time course of melatonin suppression over the 6.5 hour 
light exposure, the blue-enriched light was effective for the entire 6.5 hours whereas the 
standard lighting either failed to cause suppression or showed a loss of sensitivity over time, 
with melatonin returning to its DLMO level after an average of 2.15 hours. This is 
consistent with our previous finding that longer-wavelength monochromatic light cannot 
sustain melatonin suppression responses for more than a few hours [16,19], presumably 
through the inability of cone photoreceptors to maintain a maximal response [19,37]. When 
attempting to differentiate the relative contribution of photoreceptor systems it is useful to 
assess the light response over long durations in order to detect time course differences. 
 How classic photoreceptors participate in this phototransduction process remains an area 
of intensive investigation. Different types of ipRGCs with distinct retinal connections [38] 
further complicate the picture as perhaps these differing classes combine rod and cone 
inputs differentially leading to changing spectral sensitivities for the different evoked light 
responses. One should never assume that a light response in one area of physiology such 
as a neuroendocrine response like acute melatonin suppression will be predictive of another 
studied response such as phase shifting the circadian pacemaker. The data presented here 
illustrate that point. 
   Objective and subjective measures of alertness yielded inconsistent results.  While blue-
enriched light exposure improved subjective alertness both during and after the light 
exposure compared to standard lighting, performance improvements were only seen in the 
three hours after the light exposure, and only for auditory reaction time and lapses. While 
it is not unusual for subjective and objective measures of alertness to show inconsistent 
changes with sleep deprivation [39,40] or light exposure [41,42], further work is required 
to understand the source of these differences, including the role of visual perception in 
mediating subjective responses. 
   A number of other comparative polychromatic light studies have also failed to find 
differences in phase shifting responses [43,44,45]. Smith and colleagues did not find 
differences in phase delay or phase advance shifts but used very high, potentially saturating 
light levels (4000-6000 lux, ~4.2 x 1015 photons/cm2/s). Munch and colleagues used a 
lower intensity (1 x 1015 photons/cm2/s) closer to, but still an order of magnitude higher 
than that used in the current study (1 x 1014 photons/cm2/s), and studied older adults who 
were likely to have reduced sensitivity to blue-light given pigmentation of the lens that 
would have blocked some of the short-wavelength light [46]. While we used a quantitative 
approach in selecting our light intensity, basing it on short-duration fluence response curves 
for melatonin suppression using the same light sources, it is possible that i) short duration 
exposures (1.5 h) do not always predict the effects of longer duration light (6.5 h) [19]; ii) 
the magnitude of melatonin suppression does not predict the magnitude of circadian phase 
shifting or vice versa [47,48]. Our pre-study power calculations based on monochromatic 
exposure data showed sufficient power to detect an effect on phase shifting but our post-
hoc power calculation for phase shifting, based on the actual variances measured, 
suggested that a greater number of participants was required. 
   The blue enriched light source used appears to be more efficient for photic phase shifting 
than the standard light source . Results were compared with a prior white light PRC [8] and 
indicated that the blue enriched light stimulus achieved approximately 80% of the phase 
shifting response of the much brighter (3,000 µW/cm2) white light stimulus with the 
maximum phase-delay of -2.6 h while the standard light stimulus achieved 25% less. In 
our study, we used less than 2% (50 µW/cm2) of the energy of the white light stimulus 
reported in the PRC study.  
   The melatonin suppression data presented here are similar to the melatonin suppression 
results of other studies comparing 4000 K and 17000 K fluorescent lights. Specifically, 
compared to the 4000 K light, 17000 K light was significantly stronger in suppressing 
melatonin in healthy subjects [28,49]. Melatonin suppression has been a widely used 
marker to discern physiology of melatonin and circadian regulation [50]. Importantly, 
melatonin suppression by light is suspected to be oncogenic [51] as well as possibly 
contributing to a range of other disorders [52]. Strict numerical comparison of melatonin 
suppression values across these studies, however, is not warranted due to major protocol 
differences such as circadian time of light exposure, prior photic history, light exposure 
duration and light source geometry [8,53,54,55,56]. 
   Many studies, but not all [57,58], have shown that polychromatic light increases alertness 
and improves performance in neurobehavioral tests compared to dim light or darkness.  
The study reported here uses equal photon doses of relatively dim light. A dark control 
condition may have yielded significant results. Studies using polychromatic light reported 
alerting effects when used at night [59,60,61,62]. Neurobehavioral and physiological 
parameters affected by nocturnal bright light exposure include subjective sleepiness, EEG 
frequencies in the beta, theta and alpha ranges, psychomotor vigilance performance, and a 
variety of cognitive tests. These effects have also been shown for daytime exposure [63,64] 
consistent with a separation of the mechanisms underpinning the alertness-enhancing and 
melatonin suppression responses of light, at least during the day. 
   When comparing the alerting effects of light with different spectra, a less consistent view 
emerges. In controlled laboratory studies of monochromatic, narrow-band light and 
polychromatic light, short-wavelength sensitivity to the alerting effects of light on 
subjective and objective measures have been shown in a range of models and different 
times of day [65,66,67]. Similarly, the benefits of blue-enriched daytime light exposure on 
alertness, performance, mood and cognition have been seen in real-world settings such as 
schools, offices and care homes [23,24,25,26,27,68] and in clinical groups [69,70]. Other 
studies, however, have failed to show major differences in alertness and/or performance 
measures between different narrow-band or polychromatic sources during the day [39,71] 
or night [41].  
   Major differences in populations studied, parameters measured, light history experienced, 
timing of light exposure given and intensities employed all likely contribute to these 
findings. While there is likely too much variability between studies to conduct a formal 
review of the alerting effects of light at this time, the weight of evidence suggests that blue 
or blue-enriched lighting is likely to be beneficial for alertness and performance compared 
to spectra with less short-wavelength light, all else being equal. 
   Modeling these effects of light, or designing lighting to take advantage of these benefits 
in real world application, presents a challenge. There are multiple factors that affect these 
responses to light, including circadian timing, light intensity, wavelength and duration, but 
the field does not have a complete knowledge of all relevant factors behind such effects.  
While models have been proposed to try and predict the relative efficacy of a particular 
light stimulus in terms of its relative circadian, neuroendocrine, and neurobehavioral 
efficacy [72,73,74] caution must be exercised as our understanding of circadian 
phototransduction develops. 
   Lack of a consistent and adequate method of quantifying light between different 
laboratories publishing data on photic regulation of biological and behavioral responses 
can make it challenging to replicate experimental conditions or to compare across studies. 
A number of laboratories have collaborated on developing a consensus publication about 
measuring light for circadian, neuroendocrine and neurobehavioral regulation based on 
current and accepted sensitivity functions for rods, cones and melanopsin integrating the 
spectral power distribution of the source [75] and the Commission Internationale de 
l'Eclairage recently adopted the consensus publication and accompanying free Toolbox as 
an international standard [76].   Light source data are reported in the Figure 2 using the 
Toolbox described by Lucas and colleagues [75]. While quantification of the biological 
potency of light for non-visual photoreception is developing, collecting source descriptions 
on one platform will help for comparing results and developing testable hypotheses that 
predict spectral characteristics for targeted physiological responses to polychromatic light. 
Care must be taken to appropriately describe and measure the lighting conditions so as to 
inform the lighting community and foster intelligent design. Careful measurement of the 
incident light spectrum being studied is crucial and must be reported in a systematic way. 
To this end, the consensus methodology described by Lucas and colleagues [75] with use 
of a common nomenclature based on current and accepted sensitivity functions will open 
the door for researchers to continue to unravel this complex photosensory system. 
Meanwhile, empirical verification of specific light stimuli will remain the most accurate 
way to determine the biological potency of light sources. 
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